Physician profile
Fay Purcell
NPI 1407986292
$609.42
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $609.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $179.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $64.26 | 2021 | |
| West Therapeutics Development, LLC | $49.25 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $47.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.83 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $43.88 | 2021 | |
| Coherus Oncology, INC. | $29.52 | 2021 | |
| Daiichi Sankyo INC. | $24.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.83 | 2021 | |
| Lilly USA, LLC | $23.35 | 2021 | |
| Incyte Corporation | $23.00 | 2021 | |
| Morphosys, US INC. | $19.36 | 2021 | |
| Merck Sharp & Dohme LLC | $17.60 | 2021 | |
| Emd Serono, INC. | $17.56 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fay Purcell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.